Primary Care Providers Report a High Unmet Need for New Therapeutic Treatment Options for Chronic Kidney Disease, Despite Earlier Intervention and Referrals to Nephrologists, Spherix Reports
Spherix’s third bi-annual audit analyzed the charts of 1,002 CKD non-dialysis patients with moderate to severe kidney disease treated by primary care physicians EXTON, Pa., July 9, 2021 /PRNewswire./ – Approximately 37 million Americans have chronic kidney disease (CKD)—that is one out of every seven U.S. adults.1 Many of these patients are being managed by […]
New Research from Spherix Finds Increased Use of SGLT2 Inhibitors Across the EU5, Including AstraZeneca’s Forxiga (Farxiga in US), in the Management of IgA Nephropathy Patients
Release of second annual EU5 research on IgA nephropathy highlights unmet needs, regional diagnosis and treatment trends, and awareness of pipeline treatments, including the availability newly approved Calliditas’ Kinpeygo EXTON, Pa., August 3, 2022 /PRNewswire/ — Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as […]
High Unmet Needs Remain in Nephrology Despite Newly Approved Treatment Options According to Latest Research from Spherix Global Insights
Launch data tracking the market receptivity for Korsuva (Vifor/Cara Therapeutics), Kerendia (Bayer), Lupkynis (Aurinia Pharmaceuticals), and Tarpeyo (Calliditas) unveils gaps in patient care EXTON, Pa., June 29, 2022 / PRNewswire / – A survey of 124 US nephrologists, conducted just last week, identifies acute kidney injury (AKI), diabetic kidney disease (DKD), and polycystic kidney disease […]
European Nephrologists Lead the Way with Adoption of Astellas/FibroGen’s HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings
Recent endorsement of Evrenzo by the National Institute for Health and Care Excellence (NICE) could be a catalyst for further use as alternative to erythropoietin stimulating agents (ESAs) EXTON, Pa., June 27, 2022 / PRNewswire / – The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration […]
Lilly and Boehringer’s Jardiance Poised for Challenge to AZ’s Market Leader Farxiga in Chronic Kidney Disease: Spherix
Life science launch analyst Spherix reached that conclusion after analyzing the results of two surveys—one of 104 U.S. nephrologists and another of 330 nephrologists, cardiologists, endocrinologists and primary care doctors. While Farxiga is currently the SGLT2 inhibitor of choice among nephrologists, Spherix found Jardiance’s early trial stop has made an impression: Nearly 70% of the kidney specialists […]
Spherix Research Reveals Rheumatologists Taking the Lead Over Nephrologists in Both BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Patient Initiations in Lupus Nephritis
Nephrologists and rheumatologists are approaching the new products from very different perspectives EXTON, Pa., June 17, 2022 /PRNewswire/ —With the approvals of GlaxoSmithKline’s Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia’s Lupkynis at the beginning of 2021, practitioners now have valuable new treatment options to battle this complex condition. Spherix has been […]
New Spherix Study Reveals Jardiance (Lilly/Boehringer Ingelheim) Has Potential to Challenge Farxiga (AstraZeneca) Lead Among the Non-Diabetic CKD Population
Cross-specialty analysis on CKD and DKD patient management and evolving use of SGLT2 inhibitors shows market may be poised for a shift EXTON, Pa., / June 16, 2022/PRNewswire – As the chronic kidney disease (CKD) and diabetic kidney disease (DKD) treatment landscapes rapidly evolve, nephrologists are providing important insights to explain their increasing use of […]
Nephrologists Await Advanced Pipeline Agents, Including Venglustat (Sanofi), Lucerastat (Idorsia), and PRX-102 (Protalix), to Address High Unmet Need in Fabry Disease, Spherix Reports
Diagnosis, treatment, management, the increasing role of genetic testing, and the future promise of gene therapy captured in new report EXTON, Pa., / June 8, 2022/PRNewswire – Fabry disease is an extremely rare genetic condition most prevalent in men and potentially underdiagnosed in women. Nephrologists rank it as one of the most difficult conditions to […]
Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and Ophthalmology
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice and what baseline opinions will they be bringing as they move from a training environment into real world patient management EXTON, Pa., June 7, 2022 /PRNewswire/ — Fellows will be the next generation of practitioners. […]
Spherix Global Insights Announces Entry into Asia-Pacific Research with Upcoming IgA Nephropathy Market and Pipeline Assessment in Japan
The first IgA Nephropathy (Japan) study, due to release later this summer, pairs with other studies in the EU5 and United States EXTON, Pa., June 2, 2022 /PRNewswire/ — Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as Berger’s disease, as the most common […]
